Table 4 Multivariate analysis Reference... | American Society of Hematology

Table 4

Multivariate analysis

Reference group	NRM		Relapse/PD		Treatment failure/PFS		Mortality/OS
Reference group	P	HR	P	HR	P	HR	P	HR
Main effect	.71*/.58†	0.069*/0.026†	1.45*/2.14†	0.096*/0.003†	1.05*/1.05†	0.740*/0.788†	.96*/.84†	0.761*/0.301†
Karnofsky‡	1.51	0.011	—	—	1.43	0.004	1.48	0.002
Donor type§	2.32	< 0.001	—	—	—	—	—	—
Disease status‖	2.79/1	< 0.001‖/—	2.06‖/3.23¶	0.006‖/0.002¶	2.49‖/1.47¶	< 0.001‖/0.056¶	2.37‖/—	< 0.001‖/—
No rituximab before alloHCT#	—	—	1.69	0.008	—	—	—	—
Year of alloHCT**	.49	< 0.001	—	—	.61	< 0.001	.60	< 0.001

Reference group	NRM		Relapse/PD		Treatment failure/PFS		Mortality/OS
Reference group	P	HR	P	HR	P	HR	P	HR
Main effect	.71*/.58†	0.069*/0.026†	1.45*/2.14†	0.096*/0.003†	1.05*/1.05†	0.740*/0.788†	.96*/.84†	0.761*/0.301†
Karnofsky‡	1.51	0.011	—	—	1.43	0.004	1.48	0.002
Donor type§	2.32	< 0.001	—	—	—	—	—	—
Disease status‖	2.79/1	< 0.001‖/—	2.06‖/3.23¶	0.006‖/0.002¶	2.49‖/1.47¶	< 0.001‖/0.056¶	2.37‖/—	< 0.001‖/—
No rituximab before alloHCT#	—	—	1.69	0.008	—	—	—	—
Year of alloHCT**	.49	< 0.001	—	—	.61	< 0.001	.60	< 0.001

— indicates not applicable; and PIF, primary induction failure.

RIC-resistant versus MAC (reference group).

NMAC versus MAC (reference group).

< 90% versus ≥ 90% (reference group).

Other versus sibling MRD (reference group).

Relapse-resistant versus sensitive (reference group).

PIF-resistant versus sensitive (reference group).

Versus used.

After 2004 vs before 2004 (reference group).